Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Gia Nemsadze"'
Autor:
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Siyu Li, Yuntong Li, Manika Kaul, Ruben G.W. Quek, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Journal of Thoracic Oncology. 18:755-768
Autor:
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno-Jaime, Rodolfo Passalacqua, Siyu Li, Kristina McGuire, Manika Kaul, Anne Paccaly, Ruben G. W. Quek, Bo Gao, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Nature Medicine. 28:2374-2380
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer
Autor:
Tamta Makharadze, Ruben G. W. Quek, Tamar Melkadze, Miranda Gogishvili, Cristina Ivanescu, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, Gerasimos Konidaris, Petra Rietschel, Giuseppe Gullo
Publikováno v:
Cancer.
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Autor:
Myria Nikolaou, Timothy J. Perren, Gia Nemsadze, Richard D. Baird, Robert McEwen, Daniel Stetson, Duncan Wheatley, A.M. Brunt, Hayley Cartwright, Max McLaughlin-Callan, Jean-Marc Ferrero, Peter Schmid, Cheryl Lawrence, Jacinta Abraham, Nicholas C. Turner, László Mangel, Melissa Phillips, Matthew Burgess, Peter Hall, John Conibear, Andrew Foxley, Aaron Prendergast, Kelly Mousa, Robert Stein, Yeon Hee Park, Javier Cortes, Stephen Chan, Elza C. de Bruin, Brian Dougherty
Publikováno v:
Cancer Research. 81:PD1-11
Background: In the PAKT study, addition of the oral AKT inhibitor capivasertib to 1st-line paclitaxel therapy for metastatic TNBC resulted in significantly longer progression-free survival (PFS; primary endpoint; Schmid, J Clin Oncol 2020). The strat
Autor:
Mafalda Oliveira, Denys Pominchuck, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Yuriy Semegen, Vladmir Vladmirov, Claudio Zamagni, Hannelore Denys, Frederic Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Bennett, Bistra Kirova, Teresa Klinowska, Justin Lindemann, Delphine Lissa, Alastair Mathewson, Christopher Morrow, Zuzana Traugottova, Ruaan Van Zyl, Ekaterine Arkania
Publikováno v:
Cancer Research. 83:GS3-02
Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) in the Phase 1 SERENA-1 study1,2 with a dose-dependent safety profil
Autor:
A.M. Brunt, John Conibear, Aaron Prendergast, Nicholas C. Turner, László Mangel, Robert McEwen, Peter Schmid, Jean-Marc Ferrero, Andrew Foxley, Cheryl Lawrence, Kelly Mousa, Jacinta Abraham, Robert Stein, Gia Nemsadze, Hayley Cartwright, Melissa Phillips, Matthew Burgess, Max McLaughlin-Callan, Brian Dougherty, Shah-Jalal Sarker, Timothy J. Perren, Elza C. de Bruin, Yeon Hee Park, Javier Cortes, Richard D. Baird, Daniel Stetson, Stephen Chan, Duncan Wheatley, Peter Hall
Publikováno v:
Schmid, P, Abraham, J, Chan, S, Wheatley, D, Murray Brunt, A, Nemsadze, G, D. Baird, R, Hee Park, Y, Hall, P S, Perren, T, C. Stein, R, Mangel, L, Ferrero, J-M, Phillips, M, Conibear, J, Cortes, J, Foxley, A, C. de Bruin, E, McEwen, R, Stetson, D, Dougherty, B, Sarker, S-J, Prendergast, A, McLaughlin-Callan, M, Burgess, M, Lawrence, C, Cartwright, H, Mousa, K & C. Turner, N 2020, ' Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial ', Journal of Clinical Oncology, vol. 38, no. 5, pp. 423-433 . https://doi.org/10.1200/JCO.19.00368
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associ
Autor:
Antonia Perelló, Shah-Jalal Sarker, Isabel Ruiz, Andreas Makris, Elisabeth Oelmann, Cheryl Lawrence, A.M. Brunt, Anne Kendall, Joohyuk Sohn, Atiyyah Moosa, Keun Seok Lee, Gia Nemsadze, Marta Ferreira, Julien Grenier, Stephen Chan, Javier Cortes, Patricia Marosics, Michael Schenker, Peter Schmid, Catherine Harper-Wynne, Christopher J. Shepherd, John Conibear, Aaron Prendergast, Sherko Kuemmel, Matthias Zaiss, Kelly Mousa, Carike Coetzee, Janet E. Brown, Károly Máhr, Sidharth Dubey, Hartmut Kristeleit, Cristina Saura
Publikováno v:
JAMA Oncol
Importance Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8d54221b1897791291965de5b98f83
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
Autor:
Eugene Zhu, Els Vercammen, Kris Deprince, Irakli Kokhreidze, Ilya Safonov, Rubi Li, Lia Abshilava, Mikheil Janjalia, Bruce Kimelblatt, Iryna Litvin, Kuntegowda C. Lakshmaiah, Igor Bondarenko, Ranjan Kumar Mohapatra, Yaroslav Sparyk, Liang Xiu, Brian Leyland-Jones, Beka Samkharadze, Gia Nemsadze, Oksana Tarasova, Sergey Polenkov, Peter Bowers, Vitaliy Smirnov, Vladimir Vladimirov
Publikováno v:
Journal of Clinical Oncology. 34:1197-1207
Purpose An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Methods Women with hemoglobin ≤ 11.0 g/dL, receivi
Autor:
Ana Khazaradze, B Sepiashvilli, Irina Nakashidze, Tamar Tufinashvili, M. Alibegashvili, L Ramishvili, N. Kotrikadze, Sarfraz Ahmad, Gia Nemsadze, Manana Gordeziani
Publikováno v:
Gynecologic Oncology. 154:99-100
Objective To study alterations in lipid spectrum, lipid peroxidation intensity, and fatty acid (FA) spectrum in blood of women with benign & malignant uterine tumors during menopausal period. Metho...